Diverticulitis Market Anticipated to Expand Rapidly During 2023-2032, Says DelveInsight

DelveInsight's "Diverticulitis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Diverticulitis, historical and forecasted epidemiology as well as the Diverticulitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Diverticulitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diverticulitis Market Forecast
https://www.delveinsight.com/sample-request/diverticulitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Diverticulitis Market Report:
• The Diverticulitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As reported by Nallapeta et al. (2023), diverticulitis develops in roughly 4% to 15% of individuals with diverticula, with its incidence rising with age. The average age of patients hospitalized for diverticulitis is around 63 years.
• Wheat et al. (2023) found that white women experience higher hospitalization rates for diverticular disease. Although earlier research indicated a greater prevalence in men, more recent studies suggest that the incidence among women is also increasing.
• Neylan et al. (2024) reported that the incidence of diverticular disease is rising both in the United States and worldwide, largely due to the growing prevalence of key risk factors such as obesity.
• Bhatia et al. (2023) noted that diverticular abscesses occur in about 17% of patients with diverticular disease. Severe complications can include peritonitis, fistula development, and bowel strictures, while only 1-2% of patients experience diverticular perforative peritonitis, which carries a high risk of mortality.
• Key Diverticulitis Companies: Mikrobiomik, Emmaus Medical, Cosmo Pharmaceuticals, Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., and others
• Key Diverticulitis Therapies: MBK-01, Endari, Aemcolo, Mesalamine, SPD476, Rifamycin SV-MMX®, tigecycline, mesalamine, and others
• The Diverticulitis epidemiology based on gender analyzed that women are more likely than men to develop diverticulitis. However, among people younger than age 50, men are more likely to develop diverticulitis
• The Diverticulitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diverticulitis pipeline products will significantly revolutionize the Diverticulitis market dynamics.

Diverticulitis Overview
Diverticulitis is a medical condition characterized by the inflammation or infection of small pouches (diverticula) that can form along the walls of the digestive tract, typically in the colon (large intestine). These pouches can develop when weak spots in the intestinal walls give way under pressure, causing bulging pockets to form.

Get a Free sample for the Diverticulitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/diverticulitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diverticulitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diverticulitis Epidemiology Segmentation:
The Diverticulitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Diverticulitis
• Prevalent Cases of Diverticulitis by severity
• Gender-specific Prevalence of Diverticulitis
• Diagnosed Cases of Episodic and Chronic Diverticulitis

Download the report to understand which factors are driving Diverticulitis epidemiology trends @ Diverticulitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/diverticulitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diverticulitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diverticulitis market or expected to get launched during the study period. The analysis covers Diverticulitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diverticulitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diverticulitis Therapies and Key Companies
• MBK-01: Mikrobiomik
• Endari: Emmaus Medical
• Aemcolo: Cosmo Pharmaceuticals
• Mesalamine: Warner Chilcott
• SPD476: Shire
• Rifamycin SV-MMX®: Dr. Falk Pharma GmbH
• tigecycline: Pfizer
• mesalamine: SOFAR S.p.A.

Discover more about therapies set to grab major Diverticulitis market share @ Diverticulitis Treatment Landscape
https://www.delveinsight.com/sample-request/diverticulitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diverticulitis Market Drivers
• The increase in the prevalence of the disease and the demand for medications for faster and better treatment will boost the market
• The change in life style and eating habits, smoking are contributing to the market growth

Diverticulitis Market Barriers
• The current treatment options are very few for treating patients with Diverticulitis infection, which open a platform of new therapies to boost the market of Diverticulitis infection.

Scope of the Diverticulitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Diverticulitis Companies: Mikrobiomik, Emmaus Medical, Cosmo Pharmaceuticals, Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., and others
• Key Diverticulitis Therapies: MBK-01, Endari, Aemcolo, Mesalamine, SPD476, Rifamycin SV-MMX®, tigecycline, mesalamine, and others
• Diverticulitis Therapeutic Assessment: Diverticulitis current marketed and Diverticulitis emerging therapies
• Diverticulitis Market Dynamics: Diverticulitis market drivers and Diverticulitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diverticulitis Unmet Needs, KOL's views, Analyst's views, Diverticulitis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.